A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease

NCT00074984 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

BIOLOGICAL: Fabrazyme (agalsidase beta)
BIOLOGICAL: Placebo

Sponsor

Genzyme, a Sanofi Company